Form 4: Taysha Gene Therapies Director Granted Significant Equity Awards

John A. Stalfort III, a Director at Taysha Gene Therapies, Inc., received grants of 56,623 restricted stock units and 113,246 stock options on June 2, 2025, as part of his compensation.

Summary

• John A. Stalfort III, a Director of Taysha Gene Therapies, Inc. (TSHA), reported the acquisition of equity securities.
• On June 2, 2025, Mr. Stalfort was granted 56,623 restricted stock units (RSUs) at a price of $0 per unit.
• Concurrently, he was granted 113,246 stock options with an exercise price of $2.785 per share.
• Both the RSUs and stock options are set to vest on the earlier of June 2, 2026, or the next annual stockholders meeting, contingent upon Mr. Stalfort's continued service as a director.
• Following these transactions, Mr. Stalfort directly beneficially owns 1,155,224 shares of Common Stock and 113,246 stock options.
• Additionally, 884,290 shares of Common Stock are indirectly beneficially owned through the John A. Stalfort III 2018 Irrevocable Trust.

Sentiment

Score: 7

Explanation: The sentiment is positive as the equity awards align the director's interests with shareholders, which is generally viewed favorably. There are no negative operational or financial details in this specific filing.

Positives

• The granting of equity awards to a director aligns their financial interests with those of the shareholders, incentivizing long-term company performance and value creation.
• The awards serve as a retention mechanism, encouraging the director's continued service and commitment to the company's strategic objectives.

Risks

• The vesting of both the restricted stock units and stock options is subject to the reporting person's continued service as a director through the specified vesting date, meaning the awards could be forfeited if service ceases prematurely.

Future Outlook

The future vesting of the granted equity awards is contingent upon the reporting person's continued service as a director through the specified vesting date, which is the earlier of June 2, 2026, or the next annual stockholders meeting.

Industry Context

This Form 4 filing details an insider equity grant, which is a routine compensation practice across various industries, including the biotechnology and gene therapy sectors, to align management and director incentives with shareholder value.

Related Party Transactions

• Indirect beneficial ownership of 884,290 shares of Common Stock is held by Gineane Holly Stalfort, as Trustee of the John A. Stalfort III 2018 Irrevocable Trust under agreement dated as of October 25, 2018.

Stakeholder Impact

• Shareholders: The equity grants align the director's incentives with shareholder interests, potentially leading to better long-term performance and value creation.
• Employees: No direct impact on employees is indicated in this filing.

Next Steps

• Continued service of John A. Stalfort III as a director of Taysha Gene Therapies, Inc. to meet vesting conditions for the equity awards.
• Vesting of 56,623 restricted stock units and 113,246 stock options on the earlier of June 2, 2026, or the next annual stockholders meeting.

Key Dates

Keywords

Taysha Gene Therapies, TSHA, Form 4, Insider Transaction, Equity Award, Restricted Stock Unit, Stock Option, Director Compensation, Beneficial Ownership, Gene Therapy